Hayes, D Neil <br/><br/>
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Apr 2012 
 - 2056-65 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-11-0563  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma, Follicular--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Benzimidazoles--adverse effects<br/>Carcinoma<br/>Carcinoma, Papillary<br/>Diarrhea--chemically induced<br/>Exanthema--chemically induced<br/>Fatigue--chemically induced<br/>Female<br/>Genotype<br/>Humans<br/>Iodine Radioisotopes--therapeutic use<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Mutation<br/>Pharmacogenetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Thyroid Cancer, Papillary<br/>Thyroid Neoplasms--drug therapy<br/>Treatment Outcome<br/>ras Proteins--genetics